GMP Regulatory Update: MHRA, FDA & AI | Edition 34
GMP and GDP update covering MHRA recalls, FDA warning letters, EMA Annex 22 AI in GMP, medicine shortages and practical audit-readiness learning.
GXP COMPLIANCE NEWSLETTER
Kyle Winn and Adam Walker
7/8/202615 min read
Help Me GxP
Prepared for publication: 8 July 2026
Source window: 24 June to 8 July 2026
Focus: UK, EU and United States GMP / GDP
INTRODUCTION
This edition has a clear theme: evidence that remains usable when quality risk moves quickly. The most useful signals from the last 14 days sit across medicine recalls and defect notifications, sterile manufacturing warning letters, microbiology data integrity, AI in GMP, shortage and discontinuation planning, and emergency manufacturing capacity.
There were several strong regulatory and inspection signals in this window, particularly from FDA warning letters and MHRA medicine notifications. The United States recall section is intentionally short because no FDA-posted human drug recall announcement was identified in the checked public recall listing for this source window. That is source discipline, not proof that recall activity does not exist elsewhere.
This newsletter is educational. It supports awareness, discussion and professional development. It does not replace site-specific procedures, formal training, Pharmaceutical Quality Systems, Quality review, Responsible Person judgement, Qualified Person decisions, or regulatory advice.
FROM HELP ME GxP
Help Me GxP continues to focus on practical GMP and GDP education for people working across quality, manufacturing, distribution, pharmacy, aseptic services, validation, regulatory affairs and supply-chain roles.
This edition uses the updated 14-day format and the clearer Distribution heading. The aim is to make the newsletter more useful for busy professionals while keeping the evidence trail visible and avoiding padded sections.
This edition is sponsored by W2 Cleanroom Consulting. W2 supports pharma, biotech and healthcare organisations with cleanroom design, validation and compliance support, helping teams plan controlled environments and maintain practical evidence for regulated operations.
Sponsor: www.w2cleanrooms.com
NEWS IN PHARMA
Seven meaningful verified items were identified for this section during the 14-day coverage window.
1. EU: Commission launches RAMP UP pilot for medical-countermeasure manufacturing preparedness
Overview:
The European Commission announced the Rapid Agile Manufacturing Partnership for Union Protection, known as RAMP UP, on 2 July 2026. The pilot is intended to strengthen preparedness by accelerating scale-up of medical-countermeasure production across the EU, including vaccines, therapeutics, diagnostic tests, personal protective equipment and other medical devices.
For GxP teams, the practical point is that emergency manufacturing capacity is still a quality system issue. Capacity visibility, supplier readiness, technical transfer, data-sharing controls, quality agreements and validated operating models need to be credible before a crisis creates pressure to move faster.
2. EU: DG SANTE and EMA sign working arrangement with New Zealand Ministry of Health
Overview:
DG SANTE and EMA reported a working arrangement with the New Zealand Ministry of Health, incorporating Medsafe, with effect from 6 July 2026. The arrangement is intended to strengthen cooperation and exchange information on medicinal product quality, safety and efficacy.
International regulatory cooperation matters to pharmaceutical quality because supply chains, inspections, product information, safety signals and regulatory science rarely stay within one jurisdiction. For companies operating across regions, alignment does not remove local obligations, but it can increase the need for consistent evidence and clear regulatory change control.
Source: https://ec.europa.eu/newsroom/sante/newsletter-archives/77365
3. EU: EMA starts phased review for metastatic pancreatic cancer medicine
Overview:
EMA announced on 7 July 2026 that the CHMP has started a phased review of data on daraxonrasib, a medicine intended for metastatic pancreatic cancer. EMA explains that phased review evaluates data in stages as they become available, before a full marketing authorisation application is submitted.
This is a useful lifecycle signal. Faster regulatory routes still depend on quality, non-clinical and clinical evidence meeting the required standard. For CMC and quality teams, accelerated assessment does not mean informal assessment. It means the evidence package must be coherent, current and controlled earlier in the process.
Source: https://www.ema.europa.eu/en/news/ema-fast-tracks-review-medicine-metastatic-pancreatic-cancer
4. EU: PRAC product-information wording updated for signal recommendations
Overview:
EMA published new product information wording on 6 July 2026 from PRAC signal recommendations adopted at the 8-11 June 2026 PRAC meeting. The document includes wording for darolutamide and angioedema, and gemcitabine and drug reaction with eosinophilia and systemic symptoms.
This is not only pharmacovigilance background. Product information updates create downstream controls for labelling, artwork, batch release checks, regulatory commitments, training, medical information and change management. A weak change process can turn a safety signal into a documentation or supply defect.
5. EU: Tegsedi planned discontinuation creates a supply and patient-transition signal
Overview:
EMA published a Tegsedi shortage page on 3 July 2026. EMA states that the medicine will be unavailable in the EU as of the end of 2026 because the marketing authorisation holder is permanently discontinuing it for commercial reasons, and that the discontinuation is not related to a quality defect or safety issue.
For pharmaceutical teams, this shows that product lifecycle decisions can create patient and supply-chain consequences even where there is no quality defect. Market discontinuation still requires controlled communication, alternatives planning, shortage monitoring and clear responsibility between MAH, regulators, healthcare professionals and supply-chain partners.
Source: https://www.ema.europa.eu/en/medicines/human/shortages/tegsedi
6. UK: MHRA June Safety Roundup consolidates product safety, recall and reporting signals
Overview:
MHRA published its June 2026 Safety Roundup on 30 June 2026. The page summarises safety advice, direct healthcare professional communications, medicine recalls and notifications, device notifications and Yellow Card reporting reminders.
For GxP readers, the value is not only the individual items. Roundups help teams check whether pharmacovigilance, defect, recall, complaint, product information and training systems are receiving the same external signals. If a safety communication appears externally but never enters the local quality system, the site has an intelligence gap.
Source: https://www.gov.uk/drug-device-alerts/mhra-safety-roundup-june-2026
7. US: FDA warning letter to Genzyme Ireland highlights biologics quality oversight
Overview:
FDA posted a warning letter to Genzyme Ireland Limited on 30 June 2026, with the letter dated 22 June 2026. The letter concerns licensed biological products and describes CGMP issues including quality-unit oversight, laboratory record completeness, environmental monitoring traceability and deviation governance.
The GxP learning is direct: data integrity is not a laboratory-only issue. If the quality unit cannot detect, prevent and investigate unreliable records, repeated tests, untraceable monitoring data or cancelled deviations, the wider product-quality system is not under control.
NEWS IN DISTRIBUTION
Five meaningful verified distribution items were identified for this section during the 14-day coverage window.
1. EU: Tegsedi discontinuation requires controlled supply transition
Overview:
EMA states that Tegsedi will be unavailable in the EU as of the end of 2026 and recommends that no new patients are started on the medicine. Existing patients should be transitioned to an appropriate treatment alternative for stage 1 or stage 2 polyneuropathy due to hereditary transthyretin amyloidosis.
This is a distribution and patient-continuity issue as much as a regulatory one. Stock status, authorisation status, medical advice, national shortage registers, customer communication and final supply decisions need to remain aligned and traceable.
Source: https://www.ema.europa.eu/en/medicines/human/shortages/tegsedi
2. UK: Flucloxacillin Class 3 recall requires pharmacy and wholesaler-level stock control
Overview:
MHRA issued a Class 3 medicines recall for Flamingo Pharma UK Ltd Flucloxacillin Capsules BP 500 mg on 30 June 2026 because certain packs contained the incorrect patient information leaflet. The affected packs contained the PIL for Amoxicillin 500 mg Capsules instead of the Flucloxacillin PIL.
For distribution teams, the practical control is clear: stop supply, quarantine affected stock and return it through the approved supplier process. The notification also states that the recall applies at pharmacy and wholesaler level, so effectiveness depends on stock location visibility and rapid cascade of the recall instruction.
3. UK: Gabapentin defect notification balances quality issue with critical supply
Overview:
MHRA issued and later updated a Class 4 medicines defect notification for Gabapentin Relonchem 50 mg/ml Oral Solution. Particles had been observed in some bottles and were attributed to crystallisation of preservatives, with batch details updated on 7 July 2026 to correct one expiry date.
The affected batches were not recalled because the product was considered critical to supply. For GDP teams, this is a good example of a controlled quality-risk communication where stock checks, storage conditions, dispensing checks, customer advice and supply continuity all need to be documented.
4. US: FDA warning letter highlights online access to unapproved ketamine products
Overview:
FDA posted a warning letter to LyfeUnit on 7 July 2026, with the letter dated 23 June 2026. FDA states that the website introduced unapproved and misbranded ketamine drug products into interstate commerce, including products where the FDA-approved version is injectable or subject to REMS controls.
This is relevant to distribution because supply-chain integrity is not confined to licensed wholesalers. Online access, prescription bypass, unapproved status, unclear sourcing and injectable product risk can create patient harm outside controlled supply pathways.
5. EU: RAMP UP links manufacturing capacity visibility to emergency supply continuity
Overview:
The European Commission says the RAMP UP pilot will test processes to enhance visibility of manufacturing-capacity information relevant to future health emergencies. The data-sharing arrangements are to be developed with partners including EMA and the Executive Steering Group on Shortages and Safety of Medicinal Products.
For distribution and supply-chain functions, this is a useful signal that shortage preparedness is moving further into structured evidence. Real-time supply decisions need reliable manufacturing capacity data, secure sharing rules, escalation criteria and governance that avoids duplication while still protecting patients.
GMP / GDP REGULATORY NEWS
Six meaningful verified regulatory and inspection items were identified for this section during the 14-day coverage window.
1. EU: EudraLex Volume 4 Reference and Retention Samples revised
Overview:
The European Commission published a revised EudraLex Volume 4 document on Reference and Retention Samples on 24 June 2026. The page states that the revised document is applicable as of 24 September 2026.
This remains one of the most practical GMP updates in the current source window. Reference and retention samples support investigation capability, product traceability, complaint handling, suspected defect assessment and market-action readiness. They should not be treated as passive stored stock.
2. EU: EMA Annex 22 AI in GMP workshop held during the source window
Overview:
EMA held its GMP multistakeholder workshop on expert contributions to artificial intelligence guidance development on 30 June and 1 July 2026. EMA states that the workshop is intended to inform EU guidance on AI in medicines manufacturing, referred to as Annex 22.
The regulatory direction is important. EMA specifically frames the discussion around data governance, model evaluation, transparency, accountability, human oversight, validation, lifecycle management, cybersecurity and outsourced activities. For GMP teams, AI cannot be treated as an informal productivity tool where it influences regulated decisions or records.
3. US: Excelvision/Fareva warning letter highlights aseptic design and contamination investigation weaknesses
Overview:
FDA posted a warning letter to Excelvision/Fareva on 30 June 2026, dated 25 June 2026. The letter describes significant CGMP violations for finished pharmaceuticals, including inadequate investigation of contamination complaints, failed sterility testing events and concerns about container-closure integrity.
The letter also describes poor aseptic practices and design issues that affected unidirectional airflow. This is a direct sterile manufacturing signal: retraining alone is rarely a strong CAPA where the underlying design, flow, facility condition, intervention strategy and oversight model are weak.
4. US: Wizcure warning letter highlights serious microbiology data-integrity concerns
Overview:
FDA posted a warning letter to Wizcure Pharmaa Private Limited on 30 June 2026, dated 24 June 2026. FDA describes incomplete and unreliable laboratory records, including microbial plates with visible growth being replaced by plates showing no growth, missed environmental and personnel monitoring samples, and pre-filled laboratory forms.
This is a hard data-integrity signal for sterile operations. Microbiological monitoring is only useful if the sample identity, custody, incubation, reading, review and reporting trail can be trusted. If the evidence can be replaced or reconstructed after the event, the apparent state of control is not reliable.
5. US: Genzyme warning letter links quality-unit oversight to environmental monitoring traceability
Overview:
FDA posted a warning letter to Genzyme Ireland Limited on 30 June 2026. The letter describes quality-control unit failures, incomplete laboratory records, non-viable particulate excursions and repeated tests not documented in laboratory records, and environmental monitoring records not directly traceable to instrument histories.
The useful inspection point is that quality oversight must detect weak signals before they become systemic. Records that cannot be traced to the instrument, sampler, time, location, operator and review decision do not provide reliable evidence of environmental control.
6. US: Yangzhou Hongshengding warning letter links records access to import control
Overview:
FDA posted a warning letter to Yangzhou Hongshengding Chemical Co., Ltd. on 30 June 2026, dated 15 June 2026. FDA states that several records requests went unanswered and that the agency had no indication of the level of quality assurance for drugs listed as manufactured at the facility.
This matters for supplier qualification and import assurance. A supplier that cannot or will not provide requested quality records creates a major evidence gap. The letter also notes Import Alert 66-79 and possible detention or refusal of shipments, which turns documentation failure into a supply-chain control issue.
PHARMA RECALLS AND QUALITY DEFECTS
Three meaningful UK licensed-medicine recall or quality-defect items were identified in the source window. The FDA public recalls page was checked and no FDA-posted human drug recall announcement was identified in the visible listing for 24 June to 8 July 2026.
1. UK: Class 3 recall for Flamingo Pharma UK Ltd Flucloxacillin Capsules BP 500 mg
Overview:
MHRA issued a Class 3 medicines recall on 30 June 2026 for Flucloxacillin Capsules BP 500 mg, batch 1600636, because certain packs contained the incorrect patient information leaflet. The affected packs contained the PIL for Amoxicillin 500 mg Capsules instead of the Flucloxacillin PIL.
The recall is being undertaken as a precautionary measure at pharmacy and wholesaler level. For quality teams, the issue reinforces that printed information is a controlled component of the medicinal product and that packaging and release checks must be capable of detecting leaflet mix-ups before distribution.
2. UK: Class 4 defect notification for Brancaster benzylpenicillin benzathine
Overview:
MHRA issued a Class 4 medicines defect notification on 29 June 2026 for Brancaster Pharma Limited benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection. The affected batches were released with an outdated patient information leaflet.
The update relates to healthcare professional handling information, including aseptic preparation, reconstitution and mitigation of needle blockage risk. This is a useful reminder that leaflet and SPC changes can carry practical administration and preparation controls, not only patient-facing information.
3. UK: Updated Class 4 defect notification for Gabapentin Relonchem oral solution
Overview:
MHRA issued a Class 4 medicines defect notification for Gabapentin Relonchem 50 mg/ml Oral Solution on 30 June 2026 and updated it on 7 July 2026 to correct an expiry date for one batch. The issue relates to visible particles observed in some bottles following a customer complaint.
The investigation attributed the particles to crystallisation of preservatives, with advice on storage and visual checks. The affected batches were not recalled because the product was considered critical to supply. That makes the quality rationale, communication cascade and field actions especially important.
4. US: No FDA-posted human drug recall identified in the checked public listing
Overview:
The FDA Recalls, Market Withdrawals and Safety Alerts page was checked for the source window. In the visible listing checked on 8 July 2026, the current entries dated 25 June to 7 July were food, animal, cosmetic or supplement-related rather than human drug recall announcements.
FDA states that not all recalls have press releases or are posted on this page. This should not be interpreted as evidence that no recall activity exists elsewhere. It only reflects the checked public source used for this newsletter.
Source: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
GDP / SUPPLY-CHAIN SIGNALS
Six meaningful verified GDP or supply-chain integrity signals were identified in the source window.
1. EU: Tegsedi shortage communication shows discontinuation is a supply-chain control
Overview:
EMA states that Tegsedi is subject to an ongoing shortage and will be unavailable in the EU as of the end of 2026 because of planned discontinuation for commercial reasons. EMA also states that the discontinuation is not related to a product quality defect or safety issue.
The GDP signal is that supply-chain risk does not always start with a defect. Planned discontinuation still requires traceable communication, patient-transition planning, alternative supply routes, stock visibility and coordination between national shortage registers and competent authorities.
Source: https://www.ema.europa.eu/en/medicines/human/shortages/tegsedi
2. US: LyfeUnit warning letter shows online supply routes remain a patient-risk pathway
Overview:
FDA states that LyfeUnit offered unapproved and misbranded ketamine drug products through a website, including products where the approved version is injectable or subject to REMS controls. FDA also states that injectable products can pose serious risk because they bypass natural defences.
This is a supply-chain integrity signal. Products marketed outside authorised controls can be contaminated, counterfeit, incorrectly dosed or unsupported by approved safety controls. GDP systems should treat unauthorised online access as a real patient-risk pathway, not as a separate internet issue.
3. UK: Flucloxacillin recall tests stock segregation and return processes
Overview:
The MHRA Flucloxacillin recall instructs healthcare professionals to stop supplying the affected batch, quarantine remaining stock and return it through the supplier’s approved process. The recall applies at pharmacy and wholesaler level.
For GDP teams, this is an operational test of whether affected stock can be identified by batch, physically segregated, transactionally blocked, returned correctly and reconciled. A recall that depends on manual workarounds exposes weakness in stock-control records.
4. US: Yangzhou records refusal highlights supplier assurance and import risk
Overview:
FDA states that records requests to Yangzhou Hongshengding Chemical Co., Ltd. went unanswered after import records showed OTC drug shipments into the US market declaring the firm as manufacturer. FDA placed drugs from the firm on Import Alert 66-79 on 3 June 2026.
Supplier qualification depends on access to evidence. If a manufacturer cannot provide records that demonstrate quality assurance, the trading partner risk changes. The supply-chain question is not only whether the supplier is registered, but whether its quality system evidence can be obtained, reviewed and relied on.
5. UK: Gabapentin defect notification shows critical supply decisions need visible rationale
Overview:
MHRA states that affected Gabapentin Relonchem batches are not being recalled because the product is critical to supply. The notification instead relies on storage controls, visual checks, advice for feeding-tube use and escalation if particles are observed.
This is a useful GDP reminder that not every defect leads automatically to recall. Where supply continuity is part of the decision, the rationale must be documented, field actions must be clear, and records must show that advice reached the right points in the supply chain.
6. EU: RAMP UP pilot points to structured manufacturing and supply-chain information sharing
Overview:
The European Commission says RAMP UP will engage pharmaceutical companies to test processes that improve visibility of manufacturing capacities for future health emergencies. The arrangements are intended to be secure, proportionate and avoid duplicate data-sharing burden.
For GDP and RP teams, this signals a wider trend: supply-chain resilience increasingly depends on reliable data, defined escalation routes and shared understanding of manufacturing capacity. Poor master data and unclear accountability will weaken shortage prevention before transport or warehousing controls are even tested.
UPCOMING CONFERENCES AND TRAINING
Only two future, source-verified training items were included to avoid padding this section.
1. EMA: Mandatory use of ISO/ICH E2B(R3) Individual Case Safety Reporting training
Date: 26 to 28 October 2026
Location: Bucharest, Romania
Overview:
EMA lists a hands-on training course on the use of the EudraVigilance system for electronic reporting of ICSRs in ISO/ICH E2B(R3) format. The page states that the course is relevant for organisations aiming to register first user QPPV/RP or use EVWEB for electronic reporting to EudraVigilance for the first time.
This is primarily pharmacovigilance rather than GMP or GDP, but it remains relevant to GxP data control. Safety reporting depends on structured, timely, traceable and technically valid data exchange.
Source:
2. FDA: CDER SBIA Learn training hub and July ClinicalTrials.gov webinars
Date: ongoing resource, with July 2026 webinars listed
Location: Online
Overview:
FDA CDER SBIA Learn lists training resources, on-demand material and future live events. The checked page includes filters and topics relevant to GxP professionals, including CGMP, CMC, inspections, drug quality, drug supply chain, DSCSA, wholesalers and distributors. It also lists three July 2026 ClinicalTrials.gov webinars.
For teams working with US expectations, this is a useful official training hub. It should not replace local training requirements, but it can support awareness of FDA terminology, regulatory processes and recurring inspection themes.
Source:
AUDIT READINESS TIP
Theme: Microbiology and environmental monitoring records must prove the state of control.
The strongest audit signal this edition comes from the FDA warning letters to Wizcure, Genzyme and Excelvision/Fareva. The detail differs by site, but the pattern is consistent: weak microbiology data, incomplete laboratory records, repeated or missing samples, poor traceability to instrument histories, and contamination investigations that did not support the claimed state of control.
Practical checks for your next audit:
Can one viable and one non-viable sample be traced from collection point, time and operator through to incubation, reading, review and final trend?
Do environmental monitoring records reconcile with instrument histories, sampler IDs, room entry records and batch timing?
Are repeated tests, failed plates, missing samples and invalidated results documented, justified and investigated?
Are microbiology plates uniquely labelled, controlled through custody and reconciled at each handling step?
Do contamination complaints trigger review of EM, personnel monitoring, product contact controls, container-closure integrity and facility design?
Does CAPA address oversight, system design and working practice, or does it rely mainly on retraining?
If microbiology or EM records can be replaced, discarded, repeated silently or cannot be traced, they do not prove control. They only create the appearance of control.
Sources:
GxP FACT
FDA states that not all recalls have press releases or are posted on its Recalls, Market Withdrawals and Safety Alerts page.
That matters for this newsletter and for internal quality systems. Public recall pages are useful signals, but they are not the whole recall universe. A mature organisation still needs internal defect intake, complaint trending, supplier communication, regulatory intelligence, customer notification routes and recall simulation evidence.
Source:
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
CALL TO ACTION
This edition was intentionally selective. The 14-day window captured several strong signals, but the newsletter still avoids filling space with weak or marginal items.
If this edition is useful, share it with colleagues in QA, QC, Production, Warehouse, Distribution, Regulatory Affairs, Responsible Person teams, QPs, pharmacists, aseptic services and supply-chain roles.
Help Me GxP will continue to cover GMP and GDP together because product quality does not stop at manufacture, release or dispatch.
This edition is sponsored by W2 Cleanroom Consulting: www.w2cleanrooms.com
Kyle Winn / Adam Walker
Help Me GxP
HASHTAGS
#GxP #GMP #GDP #Pharma #QualityAssurance #MHRA #EMA #FDA #PharmaceuticalManufacturing #PharmaceuticalDistribution #SupplyChainIntegrity #InspectionReadiness #PatientSafety
Contact
Get in touch
info@w2cleanrooms.com
© 2026. All rights reserved.
Our Brands
Free GxP Training
